Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The HOPE TIPS: the HOPE study translated into practices.

Norman Sharpe1,

  • 1University of Auckland, PO Box 17160, Greenlane, Auckland 1130, New Zealand. NormanS@nhf.org.nz

Cardiovascular Drugs and Therapy
|September 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The National Heart Foundation of New Zealand: reviewing the past, the present and future challenges.

Heart, lung & circulation·2015
Same author

Rheumatic fever: from disease targeting to child-centredness.

The New Zealand medical journal·2012
Same author

Rheumatic fever in New Zealand: from perennial failure to successful eradication.

The New Zealand medical journal·2011
Same author

New Zealand's shocking diabetes rates can be reduced--9 urgently needed actions.

The New Zealand medical journal·2011
Same author

Inequities in health and the Marmot Symposia: time for a stocktake.

The New Zealand medical journal·2011
Same author

Once-daily amoxicillin for Group A Streptococcal (GAS) sore throat as the other first-line option: a clarification of the NZ sore throat guidelines.

The New Zealand medical journal·2011

Ramipril titration to 10 mg daily is practical and well-tolerated in high cardiovascular risk patients. Most patients achieved the target dose, demonstrating good tolerability in real-world clinical practice.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Practice Research

Background:

  • High cardiovascular risk necessitates effective and tolerable antihypertensive treatments.
  • Ramipril is a widely used angiotensin-converting enzyme inhibitor for cardiovascular risk reduction.

Purpose of the Study:

  • To evaluate the feasibility and tolerability of ramipril dose titration to 10 mg daily in a large, diverse patient cohort.
  • To assess ramipril's safety profile in a real-world clinical setting for patients at high cardiovascular risk.

Main Methods:

  • The HOPE TIPS study enrolled 3881 high cardiovascular risk patients across 9 countries.
  • Ramipril dosage was titrated from 2.5 mg to a target of 10 mg daily over 9-12 weeks.
  • Data on dose achievement, tolerability, and adverse events were collected from primary and specialist care settings.

Related Experiment Videos

Main Results:

  • 73% of patients successfully reached the target ramipril dose of 10 mg daily; 96% achieved 5 mg or 10 mg.
  • Treatment discontinuation was low (9.8%), with side-effects (5.9%) and cough (4%) being the main reasons.
  • Adverse cardiovascular events, including uncontrolled hypertension, myocardial infarction, heart failure, and new diabetes, were infrequent.

Conclusions:

  • Ramipril titration to 10 mg daily is a practical and well-tolerated strategy for managing high cardiovascular risk patients in clinical practice.
  • The study supports the use of ramipril as an effective and safe treatment option for this patient population.